WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526632
CAS#: 432-60-0
Description: Allylestrenol is a dose-dependent inhibitor of AR activity, used to prevent threatened miscarriage, recurrent pregnancy loss, premature labor, and benign prostatic hyperplasia.
Hodoodo Cat#: H526632
Name: Allylestrenol
CAS#: 432-60-0
Chemical Formula: C21H32O
Exact Mass: 300.25
Molecular Weight: 300.486
Elemental Analysis: C, 83.94; H, 10.73; O, 5.32
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Allylestrenol
IUPAC/Chemical Name: (8R,9S,10R,13S,14S,17R)-13-Methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
InChi Key: ATXHVCQZZJYMCF-XUDSTZEESA-N
InChi Code: InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1
SMILES Code: O[C@@]1(CC=C)CC[C@@]2([H])[C@]3([H])CCC4=CCCC[C@]4([H])[C@@]3([H])CC[C@]12C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 300.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Aspers RL, Geutjes PE, Honing M, Jaeger M. Using indirect covariance processing for structure elucidation of small molecules in cases of spectral crowding. Magn Reson Chem. 2011 Jul;49(7):425-36. doi: 10.1002/mrc.2766. Epub 2011 May 17. PubMed PMID: 21590729.
2: Shi X, Wu Y, Hang T, Xu X, Ding L, Tian Y, Wen A. Application of a sensitive liquid chromatographic/tandem mass spectrometric method to a pharmacokinetic study of allylestrenol in healthy Chinese female volunteers. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Aug 1;871(1):90-4. doi: 10.1016/j.jchromb.2008.06.054. Epub 2008 Jul 6. PubMed PMID: 18639502.
3: Urushibara M, Ishioka J, Hyochi N, Kihara K, Hara S, Singh P, Isaacs JT, Kageyama Y. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate. 2007 Jun 1;67(8):799-807. PubMed PMID: 17373727.
4: Noguchi K, Suzuki K, Teranishi J, Kondo K, Kishida T, Saito K, Uemura H, Kubota Y. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia. Hinyokika Kiyo. 2006 Jul;52(7):527-30. PubMed PMID: 16910584.
5: Kawashima H, Tanaka T, Cheng JS, Sugita S, Ezaki K, Kurisu T, Nakatani T. Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells. Urol Res. 2004 Dec;32(6):406-10. Epub 2004 Aug 14. PubMed PMID: 15316697.
6: Noguchi K, Takeda M, Hosaka M, Kubota Y. [Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]. Hinyokika Kiyo. 2002 May;48(5):269-73. Japanese. PubMed PMID: 12094708.
7: Csaba G, Karabélyos C, Inczefi-Gonda A. Effect of tamoxifen treatment at adolescent age on the sexual behaviour and steroid hormone receptor binding of adult female rats. Acta Physiol Hung. 2001;88(2):131-7. PubMed PMID: 11999805.
8: Csaba G, Inczefi-Gonda A. Similarities and dissimilarities of newborn and adolescent rats in the binding capacity of thymic glucocorticoid receptors. Mech Ageing Dev. 2001 Mar;122(3):327-34. PubMed PMID: 11311319.
9: Noguchi K, Uemura H, Takeda M, Sekiguchi Y, Ogawa K, Hosaka M. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia]. Hinyokika Kiyo. 2000 Sep;46(9):605-7. Japanese. PubMed PMID: 11107528.
10: Katona Z, Vincze L, Végh Z, Trompler A, Ferenczi-Fodor K. Cleaning validation procedure eased by using overpressured layer chromatography. J Pharm Biomed Anal. 2000 Mar;22(2):349-53. PubMed PMID: 10719918.
11: Zivanovic L, Vojvodic L, Ristic P, Zecevic M, Nemcova I. Validation and application of the RP-HPLC method for the assay of allylestrenol and alpha-tocopherol in tablets. Biomed Chromatogr. 2000 Feb;14(1):56-7. PubMed PMID: 10664567.
12: Karabélyos C, Horváth C, Holló I, Csaba G. Effect of perinatal synthetic steroid hormone (allylestrenol, diethylstilbestrol) treatment (hormonal imprinting) on the bone mineralization of the adult male and female rat. Life Sci. 1999;64(9):PL105-10. PubMed PMID: 10075115.
13: Martelli A, Mereto E, Ghia M, Orsi P, Allavena A, De Pascalis CR, Brambilla G. Induction of micronuclei and of enzyme-altered foci in the liver of female rats exposed to progesterone and three synthetic progestins. Mutat Res. 1998 Nov 9;419(1-3):33-41. PubMed PMID: 9804880.
14: Noguchi K, Harada M, Masuda M, Takeda M, Kinoshita Y, Fukushima S, Miyai K, Fukuoka H, Hosaka M. Clinical significance of interruption of therapy with allylestrenol in patients with benign prostatic hypertrophy. Int J Urol. 1998 Sep;5(5):466-70. PubMed PMID: 9781436.
15: Csaba G, Inczefi-Gonda A. Imprinting of thymic glucocorticoid receptor and uterine estrogen receptor by a synthetic steroid hormone at different times after birth. Gen Pharmacol. 1998 May;30(5):685-7. PubMed PMID: 9559318.
16: Csaba G, Inczefi-Gonda A. Effect of combined neonatal imprinting by vitamin A, vitamin D3, benzpyrene and allylestrenol on adult rat thymus glucocorticoid and uterine estrogen receptors. Gen Pharmacol. 1997 Nov;29(5):779-81. PubMed PMID: 9347325.
17: Yasuda N, Fujino K, Shiraji T, Nambu F, Kondo K. Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats. Jpn J Pharmacol. 1997 Jul;74(3):243-52. PubMed PMID: 9268084.
18: Kurita Y, Masuda H, Suzuki K, Fujita K, Kawabe K. Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. Br J Urol. 1997 Jul;80(1):78-83. PubMed PMID: 9240185.
19: Inami M, Kawamura I, Naoe Y, Tsujimoto S, Mizota T, Manda T, Shimomura K. Effects of a new non-steroidal 5 alpha-reductase inhibitor, FK143, on the prostate gland in beagle dogs. Jpn J Pharmacol. 1997 Jun;74(2):187-94. PubMed PMID: 9243327.
20: Csaba G, Inczefi-Gonda A. Effect of neonatal allylestrenol treatment and adult benzpyrene treatment on rat thymus glucocorticoid receptors. Gen Pharmacol. 1996 Dec;27(8):1387-9. PubMed PMID: 9304412.
